Eli Lilly And Company

This phase 3 trial tests mirikizumab, an experimental drug, in 90 children with moderate-to-severe Crohn's disease. The study looks at whether the drug can improve symptoms and heal the gut lining over 52 weeks. Participants receive the drug by IV or injection during a 12-week in…

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…

This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is injected into the spine to see if it is safe and how the body handles it. The main goal is to check for side effects, not yet to prove it works.

This early-stage study tests a new drug called LY4006896 in healthy volunteers and people with Parkinson's disease. The main goal is to check if the drug is safe and how the body processes it. Around 127 participants will receive either the drug or a placebo by IV. This is a firs…

This early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …

This study tests the drug tirzepatide in 344 Indian adults with type 2 diabetes or obesity/overweight. Participants receive weekly injections for 46 weeks to see if the drug is safe and helps with weight loss and blood sugar control. The goal is to gather local data on how well t…

This study tests an experimental drug called LY3457263 in people with type 2 diabetes who are already taking semaglutide or tirzepatide but still have high blood sugar levels. About 240 participants will receive either the new drug or a placebo once a week for around 9 months. Th…

This study tests whether a weekly injection of tirzepatide helps adolescents with obesity and related health problems lose weight and improve conditions like high blood pressure or prediabetes. About 300 teens will receive either tirzepatide or a placebo, along with healthy lifes…

This early-stage study tests a new drug called LY3971297 in healthy volunteers, people with obesity and high blood pressure, and those with reduced kidney function. The main goal is to check for side effects and measure how the drug moves through the body. The study involves up t…

This phase 3 trial tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. The goal is to see if the combination can reduce both gut symptoms and bod…

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…

This early-stage trial is testing a new injectable drug called retatrutide in 95 adults with type 2 diabetes. The study compares retatrutide to a placebo and to another diabetes drug, semaglutide, to see how it affects insulin production and sensitivity over 28 weeks. Participant…

This study tests whether adding the weight-loss drug tirzepatide to the Crohn's drug mirikizumab helps people with moderate-to-severe Crohn's disease who are also overweight or have obesity. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide. T…

This early-stage trial tests an experimental drug called LY4006895 in healthy volunteers and people with early symptomatic Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. The study has two parts: a single dose in healthy people an…

This study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (patchy hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, then all can get the drug for up to 2 years. The goal is to s…

This study tests an investigational drug called lebrikizumab in people with long-term sinus inflammation and nasal polyps. About 510 adults will receive either the drug or a placebo, while all continue using standard steroid nasal sprays. The goal is to see if the drug can improv…

This program allows individual patients with serious or life-threatening conditions to request early access to retatrutide before it is fully approved. The drug is intended to help control the disease, but ongoing management may still be needed. Eligibility is determined on a cas…

This early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug. The study lasts…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This early-stage study tests a new drug called brenipatide in 150 healthy adults with overweight or obesity. Participants receive injections under the skin to see how different doses affect body weight and safety. The study lasts about 42 weeks and aims to find out if the drug ca…

This study tests a once-daily pill called orforglipron to help teenagers with obesity or overweight lose weight. About 150 teens will take either the pill or a placebo for 18 months, along with lifestyle advice. The goal is to see if the pill safely reduces body mass index (BMI) …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo for up to 12 months. The study looks at weight changes, cognitive function, and time to relapse…

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shr…

This study creates a common framework to test multiple new cancer drugs in children and young adults (ages up to 21) with different types of cancer. About 105 participants will join, and each will receive a drug tailored to their specific cancer. The goal is to run several smalle…

This study tests whether adding a new drug, LY4268989, to the existing treatment mirikizumab works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab alone for up to 104 we…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This phase 3 study tests whether brenipatide, an injectable drug, can help adults with moderate-to-severe alcohol use disorder drink less and feel less craving. About 1100 participants will receive either brenipatide or a placebo for 56 weeks. The study tracks changes in drinking…

This Phase 2 trial is testing several experimental drugs—including tirzepatide and eloralintide—for chronic weight management in adults with obesity or overweight. About 1,481 participants will receive one of the drugs or a placebo. The goal is to see if these treatments are safe…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This phase 2 trial tests whether donanemab, an antibody that clears amyloid plaques, can slow cognitive and functional decline in people with early Lewy body dementia who also have amyloid and alpha-synuclein buildup. About 350 participants will receive donanemab or a placebo for…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This study tests whether adding a new drug (LY4395089) to an existing treatment (mirikizumab) works better than mirikizumab alone for adults with moderate-to-severe Crohn's disease. About 60 participants will be followed for 62 weeks to check safety and how well the combination r…

This study tests whether the experimental drug brenipatide can reduce asthma attacks and improve breathing in adults whose moderate-to-severe asthma is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The…

This study tests whether adding the drug brenipatide to standard treatment can delay the return of bipolar symptoms compared to a placebo. About 400 adults with bipolar I or II will self-inject the study drug or placebo for at least 6 months. The main goal is to see how long it t…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This study tests an oral drug called LY4268989 (MORF-057) in 1431 adults with moderate to severe ulcerative colitis. Half will get the drug, half a placebo, to see if it safely helps control symptoms and achieve remission. The trial lasts about 2 years and requires participants t…

This study tests two experimental drugs, retatrutide and tirzepatide, to see if they can prevent major liver complications like cirrhosis and liver failure in adults with high-risk metabolic fatty liver disease (MASLD). About 4,500 participants will be randomly assigned to receiv…

This early-stage study is testing a new medicine called LY4167586 in people who are overweight or have obesity but are otherwise healthy. The main goal is to see if the drug is safe and how the body processes it after a single dose. About 84 participants will be randomly assigned…

This study tests an experimental medicine called brenipatide to see if it helps adults with alcohol use disorder drink less and reduce cravings. About 1,100 participants will receive either the drug or a placebo by injection for nearly a year. The goal is to find a safe, effectiv…

This study tests a new medicine called LY3938577 against a standard insulin (degludec) in 100 adults with type 2 diabetes who already use basal insulin. The goal is to see if the new drug helps keep blood sugar in a healthy range more safely and effectively over about 26 weeks. P…

This study allows cancer patients who were getting benefit from an experimental drug in a previous Eli Lilly study to keep receiving that drug after the earlier study ends. It is designed for people who have no other good treatment options and whose doctor agrees continued access…

This study is testing several new treatments for adults with moderate to severe ulcerative colitis or Crohn's disease. About 60 participants will be randomly assigned to receive one of the study treatments or a placebo. The goal is to see if these treatments can safely control th…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study tests a new once-weekly injection called eloralintide to help adults with obesity or overweight lose weight. About 1980 people who do not have type 2 diabetes will take part for up to 75 weeks, with some continuing for 2 more years. The goal is to see if the drug safel…

This study is testing whether adding the drug donanemab to standard care helps people with early Alzheimer's stay independent longer. Researchers will follow about 6,250 participants for over 5 years, tracking when they need more help with daily tasks. The goal is to see if donan…

This study tests a new weekly injection called eloralintide in 900 adults with obesity or overweight who are already taking a weekly incretin drug (like Ozempic or Wegovy) but still have excess weight. Participants will receive either eloralintide or a placebo for about 80 weeks …

This study tests a new drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The drug is given through a vein and compared to a placebo to see if it safely reduces the size of the patches. The trial lasts about 48 weeks…

This study tests whether adding an experimental drug called brenipatide to standard addiction treatment (buprenorphine) helps people with opioid use disorder stay off opioids longer. About 465 participants will receive either brenipatide or a placebo injection for up to 144 weeks…

This study tests whether adding a new drug called brenipatide to standard depression treatment can delay the return of major depressive symptoms. About 1000 adults with major depression who are already on stable medication will receive either brenipatide or a placebo as a shot, p…

This study tests a daily pill called orforglipron to see if it can prevent major heart problems (like heart attacks or strokes) and slow kidney disease in people who already have heart or kidney disease. About 7,140 adults will take either the drug or a placebo for up to 5 years.…

This study tests whether adding the experimental drug LY3537982 to standard treatments helps people with advanced KRAS G12C-mutant non-small cell lung cancer live longer without their cancer growing. About 1,264 participants will receive either the new combination or standard car…

This study tests a new drug called eltrekibart, given alone or with another drug (mirikizumab), in 140 adults with moderate-to-severe ulcerative colitis. The goal is to see if the treatment can reduce symptoms and help the colon heal. Participants must have tried other treatments…

This study tests whether baricitinib, a daily pill, is safe and works for children aged 1 to under 18 with systemic juvenile idiopathic arthritis (sJIA), a chronic inflammatory disease. About 58 children will receive either baricitinib or a standard injected drug (tocilizumab) to…

This early-stage study tests a new drug called LY3938577 in healthy volunteers and people with type 1 diabetes. Researchers want to see how the drug moves through the body, how safe it is, and how well it controls blood sugar compared to a standard insulin. The study has four par…

This study tests a new drug, LY4337713, that delivers radiation directly to cancer cells with a specific protein called FAP. It is for adults with advanced or spread cancers like pancreatic, breast, ovarian, or colorectal cancer. The main goals are to check safety, side effects, …

This early-stage study tests a new drug called LY3954068 in 48 people with mild Alzheimer's symptoms. The drug is given directly into the spinal fluid, either once or twice, to see if it is safe and how it affects Alzheimer's markers. The study lasts up to 100 weeks and includes …

This study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…

This study tests whether adding the experimental drug olomorasib to standard immunotherapy helps people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C mutation). About 700 adults whose cancer was either surgically removed or cannot be removed will receiv…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests a drug called muvalaplin in over 10,000 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either have had a prior heart attack or stroke or are at high risk for a first event. The goal is to see if muvalap…

This study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults (ages 1 to under 36) will take either baricitinib or a placebo for 60 weeks. The goal is to see i…

This study tests a new once-weekly medicine called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for around 75 weeks. Researchers will measure changes in body weight, fat, waist …

This study tests a weekly medicine called tirzepatide to help adults with obesity (but no diabetes) lose weight and prevent type 2 diabetes. About 3000 participants will receive either tirzepatide or standard care for up to 5 years. The goal is to see if tirzepatide works better …

This study tests pirtobrutinib, an oral medication, in 58 adults with immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The first phase checks safety and side effects; the second compares different doses against a place…

This study tests a new medicine called solbinsiran in 60 adults with severely high triglycerides (a type of blood fat). Participants receive two shots and are monitored to see if the drug safely lowers their triglyceride levels compared to a placebo. The goal is to control the co…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. About 150 participants who have already been in earlier studies will continue treatme…

This study tests a new drug, STX-478, in people with advanced solid tumors that have a specific genetic mutation (PI3Kα). The drug is given alone or with other cancer treatments. The goal is to see if it is safe and shrinks tumors. About 880 adults with breast cancer or other sol…

This study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…

This study tests two experimental drugs, macupatide and eloralintide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 200 participants will take the drugs or a placebo for 48 weeks. The main goal is to see how much weight they l…

This study tests whether higher doses (3.0 mg and 4.5 mg) of the diabetes drug dulaglutide are safe and work well for teens aged 10 to 17 with type 2 diabetes. About 55 participants will take the drug for around 8 months while doctors monitor side effects, blood sugar levels, and…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study is for adults with moderate-to-severe plaque psoriasis who are also overweight or obese. Researchers want to see if adding the weight-loss drug tirzepatide to the standard psoriasis treatment ixekizumab improves skin clearance and helps people lose at least 10% of thei…

This study tests the safety and effectiveness of new medicines to help children and teens with obesity or overweight manage their weight long-term. It includes 125 participants aged 12 to 17 who have already tried lifestyle changes like diet and exercise without enough success. T…

This study is testing whether a new blood test (P-tau217) can help doctors make better decisions for people with memory complaints. About 7,000 participants will be split into groups where doctors either see the test results or not. The goal is to see if the test leads to earlier…

This early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.

This study tests whether baricitinib, an oral drug, can delay the start of type 1 diabetes in children aged 1 to 35 months who are at high risk. About 150 participants will receive either the drug or a placebo for up to 5 years. The main goal is to see how long it takes for clini…

This study tests a drug called brenipatide against a placebo to see if it can help adults who have recently quit smoking stay smoke-free. About 222 participants will receive injections for 24 weeks and be followed for 8 more weeks. The main goal is to see if more people remain ab…

This study tests an experimental drug called brenipatide for adults with irritable bowel syndrome with diarrhea (IBS-D). About 531 participants will receive either the drug or a placebo as a shot under the skin. The goal is to see if it safely reduces daily abdominal pain and imp…

This study tests whether a once-daily pill called orforglipron can reduce stress urinary incontinence (leaking urine during movement) in women with obesity or overweight. About 1000 adult women will receive either the drug or a placebo for about 58 weeks. The main goal is to see …

This study tests several experimental treatments for chronic pain conditions like knee arthritis, diabetic nerve pain, and long-term back pain. Researchers will compare each treatment to a placebo to see if it safely reduces pain. The trial aims to enroll 10,000 adults who have h…

This study tests a once-daily pill called orforglipron in 800 adults with obesity or overweight who also have painful knee osteoarthritis. The goal is to see if the drug reduces knee pain and improves physical function over about 74 weeks. Participants will be randomly assigned t…

This Phase 2 trial tests brenipatide, a drug injected under the skin, in 342 adults with irritable bowel syndrome with constipation (IBS-C). The study compares brenipatide to a placebo to see if it safely reduces abdominal pain and improves bowel movements over about 35 weeks. Pa…

This study tests whether a new drug called LY4065967 can safely reduce nerve pain in people with diabetes. About 150 adults with diabetic nerve pain in their legs for at least 6 months will receive either the study drug or a placebo. The main goal is to see if the drug lowers ave…

This study tests a single dose of an experimental painkiller (LY4515100) in 212 adults who have moderate to severe pain after having their wisdom teeth removed. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will measure pain level…

This early-stage study tests a new drug called LY4064912 in healthy adults and those with overweight or obesity. The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug and its effect on body we…

This study tests a once-weekly medicine called eloralintide in 800 adults with moderate-to-severe sleep apnea who are also overweight or have obesity. The goal is to see if it reduces breathing pauses during sleep and helps with weight loss. Some participants use a breathing mach…

This early-stage study tests a new drug called LY4057996 in 124 healthy volunteers and people with type 1 or type 2 diabetes. The main goal is to see if the drug is safe and what side effects it may cause. Participants receive the drug as a shot under the skin or into a vein, and…

This study tests a once-weekly injection called retatrutide to see if it can reduce chronic low back pain and help with weight loss in people who have obesity or overweight. About 586 participants will receive either the drug or a placebo for up to 80 weeks. The goal is to find a…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests a drug called lebrikizumab for adults with year-round allergies (perennial allergic rhinitis). The goal is to see if it reduces nasal symptoms like sneezing, stuffiness, and itching. About 450 participants will receive either the drug or a placebo, and the study …

This study tests a once-daily pill called orforglipron in about 1205 people with peripheral artery disease (PAD) who have leg pain when walking. The goal is to see if the drug helps them walk farther without pain and improves their quality of life. Participants will be followed f…

This study tests a once-weekly medicine called eloralintide in 900 adults who have both knee osteoarthritis and obesity or overweight. The goal is to see if it reduces knee pain and helps with weight loss over about 75 weeks. Participants will receive either the drug or a placebo…

This early-phase trial is testing the safety and tolerability of a new drug called LY4302814 in 150 healthy volunteers. Participants will receive either the drug or a placebo, and researchers will monitor side effects and how the body processes the drug. The study lasts about 6 m…

This early-phase trial is testing a new drug called LY4515100 in 40 healthy adults to see if it is safe and how the body handles it. Participants will receive either the drug or a placebo and stay overnight for monitoring. The study does not aim to treat any disease, but to gathe…

This early-stage study is testing an experimental drug called LY3439539 in 30 people with mild-to-moderate Alzheimer's disease. The main goal is to see if the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will receive the drug thro…

This study looks at how the antifungal drug itraconazole changes the way the body handles an experimental drug called LY4395089. Fourteen healthy adults will stay at a research unit for 15 visits over about 2 weeks, and blood tests will measure drug levels. The results will help …

This early-stage study tests three different pill forms of the experimental drug LY4065967 in 36 healthy adults. The goal is to see how much and how fast each form gets into the bloodstream and to check for side effects. Participants will stay in a research unit for three separat…

This study is testing a new drug called LY3867070 in 196 healthy volunteers to see how safe it is and how the body handles it. Participants will receive either the drug or a placebo by mouth. The main goal is to check for side effects, not to treat any disease.

This early-stage study looks at how the drug eloralintide is absorbed and tolerated in people with mild, moderate, or severe liver damage compared to those with healthy livers. About 36 participants will receive a single injection and stay at a clinic for 5 nights. The goal is to…

This study looks at how a drug called LY3537031 moves through the body in people with mild, moderate, or severe liver problems compared to healthy volunteers. About 32 adults will receive a single injection under the skin. The goal is to understand how liver function affects drug…

This study looks at how the drug eloralintide enters the bloodstream and leaves the body in people with severe kidney disease or kidney failure, compared to healthy volunteers. About 28 participants will receive a single shot under the skin. The study lasts about 14 weeks and doe…

This study follows 3,400 adults who feel their thinking is normal but may have early Alzheimer's risk based on a blood test. Over 7 years, researchers will measure memory and thinking skills to see how quickly they change. The goal is to better understand who is at risk and how t…

This early-stage study tests the safety of a new drug called LY4066708 in 104 healthy people. Researchers will measure how much drug enters the blood and brain, and how fast the body clears it. The study lasts up to 24 weeks and does not aim to treat any disease, but will help gu…

This study looks at whether a single injection of the experimental drug mirikizumab works as well as two injections in healthy people. Researchers will check safety and how the body processes the drug. About 450 healthy adults will take part, and the study lasts around 15 weeks p…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…

This early-stage study tests a new drug called LY4088044 in healthy adults to see if it is safe and how the body handles it. About 104 participants will receive the drug or a placebo, either as a shot under the skin or into a vein. The study lasts up to 92 weeks and focuses on si…